Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum

References

• Albrecht MT, Li H, Williamson ED et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun.75(11), 5425–5433 (2007).
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med.354(2), 462–471 (2006).
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis.8(8), 833–841 (2002).
   PubMed Web of Science ®Google Scholar
• Casadevall A. Antibodies for defense against biological attack. Nat. Biotechnol.20(2), 114 (2002).
   PubMed Web of Science ®Google Scholar
• Eubanks LM, Dickerson TJ, Janda KD. Technological advancements for the detection of and protection against biological and chemical warfare agents. Chem. Soc. Rev.36, 458–470 (2007).
   PubMed Web of Science ®Google Scholar
• Greenfield RA, Bronze MS. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov. Today8(19), 881–888 (2003).
   PubMed Web of Science ®Google Scholar
• Kozel TR, Murphy WJ, Brandt S et al. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc. Natl Acad. Sci. USA101(14), 5042–5047 (2004).
   PubMed Web of Science ®Google Scholar
• Sette A, Fleri W, Peters B, Sathiamurthy M, Bui HH, Wilson S. A roadmap for the immunomics of category A–C pathogens. Immunity22(2), 155–161 (2005).
   PubMedGoogle Scholar
• Spencer RC. Bacillus anthracis. J. Clin. Pathol.56(3), 182–187 (2003).
   PubMed Web of Science ®Google Scholar
• Swiecki MK, Lisanby MW, Shu F, Turnbough CL Jr, Kearney JF. Monoclonal antibodies for Bacillus anthracis spore detection and functional analyses of spore germination and outgrowth. J. Immunol.176(10), 6076–6084 (2006).
   Google Scholar
• Zhou B, Wirsching P, Janda KD. Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc. Natl Acad. Sci. USA99(8), 5241–5246 (2002).
   PubMed Web of Science ®Google Scholar
• Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N. Engl. J. Med.341(11), 815–826 (1999).
   PubMed Web of Science ®Google Scholar
• Vitale L, Blanset D, Lowy I et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun.74(10), 5840–5847 (2006).
   PubMed Web of Science ®Google Scholar
• Peterson JW, Comer JE, Baze WB et al. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun.75(7), 3414–3424 (2007).
   PubMed Web of Science ®Google Scholar
• Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T-cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl Acad. Sci. USA104(1), 246–251 (2007).
   PubMed Web of Science ®Google Scholar
• Vita R, Vaughan K, Zarebski L et al. Curation of complex, context-dependent immunological data. BMC Bioinformatics7, 341–348 (2006).
   PubMed Web of Science ®Google Scholar
• Peters B, Sidney J, Bourne P et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol.3(3), e91 (2005).
   PubMed Web of Science ®Google Scholar
• Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev.68(3), 373–402 (2004).
   PubMed Web of Science ®Google Scholar
• Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem.76, 243–265 (2007).
   PubMed Web of Science ®Google Scholar
• Mosser EM, Rest RF. The Bacillus anthracis cholesterol-dependent cytolysin, Anthrolysin O, kills human neutrophils, monocytes and macrophages. BMC Microbiol.656 (2006).
   Google Scholar
• Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA285(8), 1059–1070 (2001).
   PubMed Web of Science ®Google Scholar
• Schiavo, G. Structural biology: dangerous liaisons on neurons. Nature444, 1019–1020 (2006).
   Google Scholar
• Blöcker D, Barth H, Maier E, Benz R, Barbieri JT, Aktories K. The C terminus of component C2II of Clostridium botulinum C2 toxin is essential for receptor binding. Infect. Immun.68(8), 4566–4573 (2000).
   PubMed Web of Science ®Google Scholar
• Aktories K, Bärmann M, Ohishi I, Tsuyama S, Jakobs KH, Habermann E. Botulinum C2 toxin ADP-ribosylates actin. Nature322, 390–392 (1986).
   PubMed Web of Science ®Google Scholar
• Brodzik R, Bandurska K, Deka D, Golovkin M, Koprowski H. Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta. Biochem. Biophys. Res. Commun.338(2), 717 (2005).
   PubMed Web of Science ®Google Scholar
• Goyard S, Orlando C, Sabatier JM et al. Identification of a common domain in calmodulin-activated eukaryotic and bacterial adenylate cyclases. Biochemistry28(5), 1964–1967 (1989).
   PubMed Web of Science ®Google Scholar
• Gubbins MJ, Berry JD, Corbett CR et al. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol.47(3), 436–443 (2006).
   PubMed Web of Science ®Google Scholar
• Kozel TR, Thorkildson P, Brandt S et al. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect. Immun.75(1), 152–163 (2007).
   PubMed Web of Science ®Google Scholar
• Laffly E, Danjou L, Condemine F et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob. Agents Chemother.49(8), 3414–3420 (2005).
   PubMed Web of Science ®Google Scholar
• Lim NK, Kim JH, Oh MS et al. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun.73(10), 6547–6551 (2005).
   PubMed Web of Science ®Google Scholar
• Little SF, Novak JM, Lowe JR et al. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology142(3), 707–715 (1996).
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Danthinne X, Imperiale MJ. Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol.80(11), 5361–5370 (2006).
   PubMed Web of Science ®Google Scholar
• Mehta AS, Saile E, Zhong W et al. Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium. Chemistry12(36), 9136–9149 (2006).
   PubMed Web of Science ®Google Scholar
• Reed DS, Smoll J, Gibbs P, Little SF. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis. Cytometry49(1), 1–7 (2002).
   PubMedGoogle Scholar
• Rosovitz MJ, Schuck P, Varughese M et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem.278(33), 30936–30944 (2003).
   PubMed Web of Science ®Google Scholar
• Schneerson R, Kubler-Kielb J, Liu TY et al. Poly(γ-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl Acad. Sci. USA100(15), 8945–8950 (2003).
   PubMed Web of Science ®Google Scholar
• Wang TT, Fellows PF, Leighton TJ, Lucas AH. Induction of opsonic antibodies to the γ-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol. Med. Microbiol.40(3), 231–237 (2004).
   PubMed Web of Science ®Google Scholar
• Wang TT, Lucas AH. The capsule of Bacillus anthracis behaves as a thymus-independent type 2 antigen. Infect. Immun.72(9), 5460–5463 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu J, Li G et al. The 2β2–2β3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem. Biophys. Res. Commun.341(4), 1164–1171 (2006).
   PubMed Web of Science ®Google Scholar
• Laughlin EM, Miller JD James E et al. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine. Infect. Immun.75(4), 1852–1860 (2007).
   PubMed Web of Science ®Google Scholar
• Musson JA, Walker N, Flick-Smith H, Williamson ED, Robinson JH. Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J. Biol. Chem.278(52), 52425–52431 (2003).
   Google Scholar
• Smith ME, Koser M, Xiao S et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology353(2), 344–356 (2006).
   PubMed Web of Science ®Google Scholar
• von Delwig A, Musson JA, Shim HK et al. Distribution of productive antigen-processing activity for MHC class II presentation in macrophages. Scand. J. Immunol.62(3), 243–250 (2005).
   Google Scholar
• Ahmed SA, Smith LA. Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. J. Protein Chem.19(6), 475–487 (2000).
   Google Scholar
• Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species. J. Protein Chem.15(7), 691–700 (1996).
   PubMedGoogle Scholar
• Atassi MZ, Dolimbek BZ. Mapping of the antibody-binding regions on the HN-domain (residues 449–859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J.23(1), 39–52 (2004).
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Dolimbek GS, Deitiker PR, Aoki KR, Dolimbek BZ. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol.42(12), 1509–1520 (2005).
   Google Scholar
• Bavari S, Pless DD, Torres ER, Lebeda FJ, Olson MA. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine16(19), 1850–1856 (1998).
   PubMed Web of Science ®Google Scholar
• Cenci Di Bello I, Poulain B, Shone CC, Tauc L, Dolly JO. Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes. Eur. J. Biochem.219(1–2), 161–169 (1994).
   Google Scholar
• Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol.44(5), 1029–1041 (2007).
   PubMed Web of Science ®Google Scholar
• Kubota T, Watanabe T, Yokosawa N et al. Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies. Appl. Environ. Microbiol.63(4), 1214–1218 (1997).
   Google Scholar
• Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol.365(1), 196–210 (2007).
   PubMedGoogle Scholar
• Oshima M, Hayakari M, Middlebrook JL, Atassi MZ. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855–1296) of the toxin. Mol. Immunol.34(14), 1031–1040 (1997).
   PubMed Web of Science ®Google Scholar
• Oshima M, Middlebrook JL, Atassi MZ. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol. Lett.60(1), 7–12 (1998).
   PubMed Web of Science ®Google Scholar
• Dolimbek GS, Dolimbek BZ, Aoki KR, Atassi MZ. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449–859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest.34(2), 119–142 (2005).
   PubMed Web of Science ®Google Scholar
• Reuveny S, White MD, Adar YY et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun.69(5), 2888–2893 (2001).
   PubMed Web of Science ®Google Scholar
• Steichen C, Chen P, Kearney JF, Turnbough CL Jr. Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J. Bacteriol.185(6), 1903–1910 (2003).
   PubMed Web of Science ®Google Scholar
• Read TD, Peterson SN, Tourasse N et al. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature423(6935), 81–86 (2003).
   PubMed Web of Science ®Google Scholar
• Subramanian GM, Cronin PW, Poley G et al. A Phase I study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis.41(1), 12–20 (2005).
   PubMed Web of Science ®Google Scholar
• Kudva IT, Griffin RW, Garren JM, Calderwood SB, John M. Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation. Infect. Immun.73(9), 5685–5696 (2005).
   PubMed Web of Science ®Google Scholar
• Baillie L, Townend T, Walker N, Eriksson U, Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol. Med. Microbiol.42(2), 267–270 (2004).
   PubMed Web of Science ®Google Scholar
• Brossier F, Levy M, Landier A, Lafaye P, Mock M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun.72(11), 6313–6317 (2004).
   PubMed Web of Science ®Google Scholar
• Chen Z, Moayeri M, Zhou YH et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis.193(5), 625–633 (2006).
   PubMed Web of Science ®Google Scholar
• Flick-Smith HC, Waters EL, Walker NJ et al. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog.38(1), 33–40 (2005).
   PubMedGoogle Scholar
• Flick-Smith HC, Walker NJ, Gibson P et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun.70(3), 1653–1656 (2002).
   PubMed Web of Science ®Google Scholar
• Rivera J, Nakouzi A, Abboud N et al. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun.74(7), 4149–4156 (2006).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Hodgson I, Walker NJ et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun.73(9), 5978–5987 (2005).
   PubMed Web of Science ®Google Scholar
• Chichester JA, Musiychuk K, de la Rosa P et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine25(6), 3111–3114 (2007).
   PubMed Web of Science ®Google Scholar
• Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun.69(7), 4509–4515 (2001).
   PubMed Web of Science ®Google Scholar
• Little SF, Leppla SH, BurnettJW, Friedlander AM. Structure–function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem. Biophys. Res. Commun.199(2), 676–682 (1994).
   PubMed Web of Science ®Google Scholar
• Zeng M, Xu Q, Hesek ED, Pichichero ME. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine24(5), 662–670 (2006).
   PubMed Web of Science ®Google Scholar
• Amersdorfer P, Wong C, Chen S et al. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Immun.65(9), 3743–3752 (1997).
   PubMed Web of Science ®Google Scholar
• Nowakowski A, Wang C, Powers DB et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl Acad. Sci. USA99(17), 11346–11350 (2002).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Lou J, Geren IN et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun.73(9), 5450–5457 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez C, Levy R et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol.25(1), 107–116 (2007).
   PubMed Web of Science ®Google Scholar
• Arndt JW, Jacobson MJ, Abola EE et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol.362(4), 733–742 (2006).
   PubMed Web of Science ®Google Scholar
• Amersdorfer P, Wong C, Smith T et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine20(11–12), 1640–1648 (2002).
   PubMed Web of Science ®Google Scholar
• Baldwin MR, Tepp WH, Pier CL et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun.73(10), 6998–7005 (2005).
   PubMed Web of Science ®Google Scholar
• Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun.66(10), 4817–4822 (1998).
   PubMed Web of Science ®Google Scholar
• Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine14(16), 1538–1544 (1996).
   PubMedGoogle Scholar
• Kozaki S, Miki A, Kamata Y, Ogasawara J, Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect. Immun.57(9), 2634–2639 (1989).
   PubMedGoogle Scholar
• Mullaney BP, Pallavicini MG, Marks JD. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect. Immun.69(10), 6511–6514 (2001).
   Google Scholar
• Pless DD, Torres ER, Reinke EK, Bavari S. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect. Immun.69(1), 570–574 (2001).
   PubMed Web of Science ®Google Scholar
• Boles J, West M, Montgomery V et al. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon47(8), 877–884 (2006).
   PubMed Web of Science ®Google Scholar
• Potter KJ, Bevins MA, Vassilieva EV et al. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr. Purif.13(3), 357–365 (1998).
   PubMed Web of Science ®Google Scholar
• Yang GH, Kim KS, Kim HW et al. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon44(1), 19–25 (2004).
   Google Scholar
• Kozaki S, Kamata Y, Nishiki T et al. Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in Japan. Infect. Immun.66(10), 4811–4816 (1998).
   Google Scholar
• Kozaki S, Ogasawara J, Shimote Y, Kamata Y, Sakaguchi G. Antigenic structure of Clostridium botulinum type B neurotoxin and its interaction with gangliosides, cerebroside, and free fatty acids. Infect. Immun.55(12), 3051–3056 (1987).
   Google Scholar
• Ochanda JO, Syuto B, Oguma K, Iida H, Kubo S. Comparison of antigenicity of toxins produced by Clostridium botulinum type C and D strains. Appl. Environ. Microbiol.47(6), 1319–1322 (1984).
   Google Scholar
• Oguma K, Agui T, Syuto B, Kimura K, Iida H, Kubo S. Four different monoclonal antibodies against type C1 toxin of Clostridium botulinum. Infect. Immun.38(1), 14–20 (1982).
   Google Scholar
• Oguma K, Murayama S, Syuto B, Iida H, Kubo S. Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies. Infect. Immun.43(2), 584–588 (1984).
   PubMed Web of Science ®Google Scholar
• Tsuzuki K, Yokosawa N, Syuto B et al. Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin. Infect. Immun.56(4), 898–902 (1988).
   Google Scholar
• Kozaki S, Kamata Y, Nagai T, Ogasawara J, Sakaguchi G. The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin. Infect. Immun.52(3), 786–791 (1986).
   PubMedGoogle Scholar
• Holley JL, Elmore M, Mauchline M, Minton N, Titball RW. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine19(2–3), 288–297 (2000).
   PubMed Web of Science ®Google Scholar
• Mohamed N, Li, J, Ferreira CS et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun.72(6), 3276–3683 (2004).
   PubMed Web of Science ®Google Scholar
• Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun.70(2), 661–664 (2002).
   PubMed Web of Science ®Google Scholar
• Wang JY, Roehrl MH. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol.4(1), 4 (2005).
   PubMedGoogle Scholar
• Welkos S, Friedlander A, Weeks S, Little S, Mendelson I. In-vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol.51(10), 821–831 (2002).
   PubMed Web of Science ®Google Scholar